292 related articles for article (PubMed ID: 33432320)
1. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges.
Krishnamoorthy M; Lenehan JG; Maleki Vareki S
J Natl Cancer Inst; 2021 Jul; 113(7):823-832. PubMed ID: 33432320
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
Ferraresi V; Vari S
Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
[TBL] [Abstract][Full Text] [Related]
3. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.
O'Donnell JS; Hoefsmit EP; Smyth MJ; Blank CU; Teng MWL
Clin Cancer Res; 2019 Oct; 25(19):5743-5751. PubMed ID: 31040150
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunotherapy for melanoma.
Lee AY; Brady MS
J Surg Oncol; 2021 Mar; 123(3):782-788. PubMed ID: 33002195
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q; Liu T; Ding Z
Front Immunol; 2022; 13():1051841. PubMed ID: 36569908
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
Maio M; Blank C; Necchi A; Di Giacomo AM; Ibrahim R; Lahn M; Fox BA; Bell RB; Tortora G; Eggermont AMM
Eur J Cancer; 2021 Jul; 152():155-164. PubMed ID: 34107449
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
10. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma.
Klein O; Brown WA; Saxon S; Haydon A
Oncologist; 2021 Jun; 26(6):461-464. PubMed ID: 33856094
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
[TBL] [Abstract][Full Text] [Related]
12. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Levine LS; Mahuron KM; Tsai KK; Wu C; Mattis DM; Pauli ML; Oglesby A; Lee JC; Spitzer MH; Krummel MF; Algazi AP; Rosenblum MD; Alvarado M; Daud AI
Ann Surg Oncol; 2020 Oct; 27(11):4122-4130. PubMed ID: 32488521
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing.
van Akkooi ACJ; Zijlker LP; Wouters MWJM
BioDrugs; 2022 May; 36(3):373-380. PubMed ID: 35397089
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Sanber K; Rosner S; Forde PM; Marrone KA
BioDrugs; 2023 Nov; 37(6):775-791. PubMed ID: 37603233
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
Spagnolo F; Croce E; Boutros A; Tanda E; Cecchi F; Mascherini M; Solari N; Cafiero F; Queirolo P
Expert Rev Anticancer Ther; 2020 May; 20(5):403-413. PubMed ID: 32326767
[No Abstract] [Full Text] [Related]
17. Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.
Miyashita M; Ishida T
Chin Clin Oncol; 2020 Jun; 9(3):28. PubMed ID: 32312056
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.
Hieken TJ; Kreidieh F; Aedo-Lopez V; Block MS; McArthur GA; Amaria RN
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390614. PubMed ID: 37116111
[TBL] [Abstract][Full Text] [Related]
19. The Role of Neoadjuvant Therapy in Melanoma.
Kelly ZR; Gorantla VC; Davar D
Curr Oncol Rep; 2020 Jun; 22(8):80. PubMed ID: 32601947
[TBL] [Abstract][Full Text] [Related]
20. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
Keung EZ; Ukponmwan EU; Cogdill AP; Wargo JA
Ann Surg Oncol; 2018 Jul; 25(7):1814-1827. PubMed ID: 29500764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]